retatrutide trial results october 2025 Timeline: Week-by-Week (48 Weeks) Retatrutide Results: 28.3% Weight Loss

To provide timely, complementary evidence, we conducted a comparison of tirzepatide and semaglutide in patients at low, moderate and high cardiovascular risk who were diagnosed with obesity and type 2 diabetes and subgroups with specific cardiovascular conditions

Participants received once-weekly subcutaneous injections of retatrutide at varying doses or placebo over 24 weeks, with a structured dose-escalation period built into the protocol to improve tolerability

Dybala et al., 2020)

The strongest positive correlation in responders was between insulin resistance HOMA IR and insulin level after GLP-1 infusion

Common temporary side effects may include: nausea constipation fatigue reduced appetite mild stomach discomfort Symptoms often improve as the body adjusts to treatment

Replication of the association of BDNF and MC4R variants with dietary intake in the diabetes prevention program